Wuhan Keqian Biology Co Ltd
SSE:688526
Income Statement
Earnings Waterfall
Wuhan Keqian Biology Co Ltd
Income Statement
Wuhan Keqian Biology Co Ltd
| Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||||||
| Interest Expense |
0
|
1
|
1
|
1
|
2
|
2
|
4
|
4
|
5
|
7
|
6
|
9
|
6
|
6
|
5
|
5
|
3
|
0
|
0
|
|
| Revenue |
843
N/A
|
1 162
+38%
|
1 033
-11%
|
1 015
-2%
|
1 103
+9%
|
987
-11%
|
952
-4%
|
1 014
+7%
|
1 001
-1%
|
1 078
+8%
|
1 139
+6%
|
1 142
+0%
|
753
-34%
|
696
-8%
|
666
-4%
|
942
+42%
|
982
+4%
|
1 029
+5%
|
1 014
-1%
|
|
| Gross Profit | ||||||||||||||||||||
| Cost of Revenue |
(147)
|
(202)
|
(187)
|
(212)
|
(224)
|
(232)
|
(237)
|
(254)
|
(272)
|
(280)
|
(304)
|
(302)
|
(227)
|
(228)
|
(244)
|
(354)
|
(363)
|
(360)
|
(352)
|
|
| Gross Profit |
696
N/A
|
960
+38%
|
846
-12%
|
803
-5%
|
880
+10%
|
755
-14%
|
715
-5%
|
760
+6%
|
730
-4%
|
798
+9%
|
835
+5%
|
840
+1%
|
526
-37%
|
468
-11%
|
422
-10%
|
588
+39%
|
619
+5%
|
668
+8%
|
662
-1%
|
|
| Operating Income | ||||||||||||||||||||
| Operating Expenses |
(209)
|
(293)
|
(259)
|
(271)
|
(289)
|
(257)
|
(277)
|
(293)
|
(335)
|
(355)
|
(350)
|
(360)
|
(224)
|
(215)
|
(199)
|
(246)
|
(257)
|
(256)
|
(217)
|
|
| Selling, General & Administrative |
(161)
|
(228)
|
(210)
|
(214)
|
(213)
|
(188)
|
(201)
|
(218)
|
(243)
|
(274)
|
(267)
|
(280)
|
(178)
|
(167)
|
(141)
|
(185)
|
(177)
|
(183)
|
(143)
|
|
| Research & Development |
(52)
|
(76)
|
(72)
|
(75)
|
(72)
|
(83)
|
(88)
|
(90)
|
(92)
|
(100)
|
(100)
|
(100)
|
(63)
|
(61)
|
(61)
|
(77)
|
(88)
|
(91)
|
(97)
|
|
| Depreciation & Amortization |
(16)
|
0
|
0
|
0
|
(18)
|
0
|
0
|
0
|
(24)
|
0
|
0
|
0
|
0
|
0
|
0
|
(18)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
20
|
11
|
23
|
19
|
14
|
14
|
12
|
15
|
25
|
19
|
17
|
20
|
17
|
13
|
3
|
34
|
8
|
18
|
23
|
|
| Operating Income |
487
N/A
|
667
+37%
|
586
-12%
|
533
-9%
|
591
+11%
|
498
-16%
|
438
-12%
|
467
+7%
|
395
-15%
|
443
+12%
|
485
+9%
|
480
-1%
|
303
-37%
|
253
-17%
|
222
-12%
|
342
+54%
|
362
+6%
|
412
+14%
|
445
+8%
|
|
| Pre-Tax Income | ||||||||||||||||||||
| Interest Income Expense |
37
|
51
|
56
|
65
|
70
|
71
|
70
|
71
|
72
|
79
|
79
|
77
|
52
|
56
|
74
|
99
|
102
|
107
|
87
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
1
|
1
|
1
|
(2)
|
0
|
0
|
0
|
|
| Gain/Loss on Disposition of Assets |
(1)
|
0
|
0
|
0
|
(2)
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
(4)
|
(4)
|
(5)
|
(5)
|
1
|
(1)
|
1
|
1
|
0
|
(2)
|
(2)
|
(1)
|
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
(0)
|
(1)
|
|
| Pre-Tax Income |
520
N/A
|
714
+37%
|
638
-11%
|
593
-7%
|
660
+11%
|
568
-14%
|
509
-10%
|
538
+6%
|
467
-13%
|
520
+11%
|
562
+8%
|
555
-1%
|
355
-36%
|
310
-13%
|
297
-4%
|
438
+48%
|
464
+6%
|
519
+12%
|
530
+2%
|
|
| Net Income | ||||||||||||||||||||
| Tax Provision |
(72)
|
(97)
|
(87)
|
(79)
|
(89)
|
(76)
|
(65)
|
(70)
|
(57)
|
(66)
|
(73)
|
(72)
|
(47)
|
(39)
|
(37)
|
(57)
|
(61)
|
(70)
|
(72)
|
|
| Income from Continuing Operations |
448
|
617
|
551
|
514
|
571
|
492
|
444
|
468
|
409
|
454
|
489
|
483
|
309
|
270
|
260
|
381
|
402
|
449
|
458
|
|
| Income to Minority Interest |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Net Income (Common) |
448
N/A
|
617
+38%
|
551
-11%
|
514
-7%
|
571
+11%
|
493
-14%
|
444
-10%
|
468
+6%
|
410
-13%
|
454
+11%
|
490
+8%
|
484
-1%
|
309
-36%
|
271
-12%
|
261
-4%
|
382
+47%
|
403
+5%
|
450
+11%
|
460
+2%
|
|
| EPS (Diluted) |
1.16
N/A
|
1.32
+14%
|
1.18
-11%
|
1.12
-5%
|
1.23
+10%
|
1.06
-14%
|
0.95
-10%
|
1.01
+6%
|
0.88
-13%
|
0.98
+11%
|
1.05
+7%
|
1.04
-1%
|
0.67
-36%
|
0.59
-12%
|
0.56
-5%
|
0.82
+46%
|
0.86
+5%
|
0.96
+12%
|
0.98
+2%
|
|